William C. Weldon

Last updated

William C. Weldon (born November 26, 1948) is a former chairman of Johnson & Johnson, [1] He was the eighth chairman in Johnson & Johnson's history of more than one hundred years. [2]

Contents

Early life and education

He was born in Brooklyn, New York. His parents were a Broadway stagehand and a costume designer. He received a Bachelor of Arts degree in biology from Quinnipiac University in 1971. [3]

Career

He spent his entire working life at Johnson & Johnson. He joined the company as a sales representative for the McNeil Pharmaceutical division in 1971 and eventually became the head of Johnson & Johnson's Ethicon Endo-Surgery business in 1992. He became the head of Johnson & Johnson's pharmaceutical operations in 1998 and then became the company's chief executive officer (CEO) in 2002. As CEO, Weldon engineered some of the largest acquisitions in the company's history including the purchase of Alza and Pfizer's consumer-health product line. [4] [5]

In 2009, he earned a total compensation of $22,830,834, which included a base salary of $1,802,500, a cash bonus of $12,831,146, stock awards of $2,762,532, option awards of $5,238,069, and other compensation of $196,587. [6] In 2011, The New York Times named him on its list of "The Worst C.E.O.'s of 2011" for the increased number of Johnson & Johnson product recalls under his leadership. [7] Additionally, as of 2013, his story was a case study at the Leadership & Corporate Accountability course at Harvard Business School. [8]

In Weldon's first full year as the company's CEO, total revenues increased from $32.3 billion to $36.3 billion and net earnings from $5.7 billion to $6.6 billion. [9] In 2011, his last full year as CEO, revenues were $44.7 billion and net earnings were $9.7 billion. [10]

Weldon retired as chairman of Johnson & Johnson on December 28, 2012, and was reported to receive $143.5 million in retirement pay. [11]

Board memberships

He also sits on the JPMorgan Chase & Co. board of directors, the HeartFlow board of directors, the ExxonMobil board of directors, the Fairfax Financial board of directors, and the Quinnipiac University board of trustees. [3]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Johnson & Johnson</span> American multinational pharmaceutical and consumer goods corporation

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Tyco International plc was a security systems company incorporated in the Republic of Ireland, with operational headquarters in Princeton, New Jersey, United States. Tyco International was composed of two major business segments: security solutions and fire protection.

<span class="mw-page-title-main">Jeff Immelt</span> American businessman

Jeffrey Robert Immelt is an American business executive currently working as a venture partner at New Enterprise Associates. He previously served as the CEO of General Electric from 2001 to 2017, and the CEO of GE's Medical Systems division from 1997 to 2000.

<span class="mw-page-title-main">John T. Chambers</span> American businessman

John Thomas Chambers is the former executive chairman and CEO of Cisco Systems.

Edmund T. Pratt Jr. was the Chairman and CEO of Pfizer Inc. He served as President from 1971 to 1972, CEO from 1972 to 1991, and Chairman from 1972 to 1992. He is the namesake of Duke University's Engineering School.

<span class="mw-page-title-main">King Pharmaceuticals</span> American pharmaceutical company

King Pharmaceuticals, is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

<span class="mw-page-title-main">Ron Williams</span> American businessperson

Ronald Allen Williams is an American Businessman, Entrepreneur and management consultant, and board director on corporate, public sector and non-profit boards. Williams is the author of Learning to Lead: The Journey to Leading Yourself, Leading Others, and Leading an Organization, which appeared on The Wall Street Journal's best seller list. He is founder, chairman and CEO of RW2 Enterprises, LLC. He is the former chairman, president and chief executive officer (CEO) of Aetna Inc., a diversified benefits company. Aetna is now part of CVS Health.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

Miles D. White is an American businessman. He had a 38-year career with Abbott Laboratories, most prominently being CEO between 1999 and 2020.

<span class="mw-page-title-main">Hospira</span>

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Jeffrey B. Kindler is an American healthcare executive and private investor. He served as chairman and CEO of the pharmaceutical company Pfizer from 2006 to 2010. Kindler has later served as CEO of Centrexion Inc., and chairman of the GLG Institute.

Ajit, Baron Shetty is a Belgian businessman. He was chairman of the board of directors of Janssen Pharmaceutica, a pharmaceutical company and subsidiary of Johnson & Johnson, with its headquarters in Beerse, Belgium. In February 2012 he retired. Shetty also served as a member of the Corporate Center Group Operating Committee and Vice President of Enterprise Supply Chain for Johnson & Johnson in New Brunswick, New Jersey.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Kenneth Frazier</span> American business executive

Kenneth Carleton Frazier is an American business executive. He is executive chairman and former CEO of the pharmaceutical company Merck & Co.. After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx. Frazier is the first African American man to lead a major pharmaceutical company. He was elected to the American Philosophical Society in 2018.

<span class="mw-page-title-main">Alex Gorsky</span> American businessman (born 1960)

Alex Gorsky is an American businessman and the executive chairman of Johnson & Johnson. He is the seventh person who served as chair and chief executive officer of Johnson & Johnson since it became a publicly traded company in 1944. Gorsky stepped down as CEO at Johnson & Johnson in January 2022 and was succeeded by Joaquin Duato.

<span class="mw-page-title-main">Sheri McCoy</span> American scientist and business executive

Sherilyn S. McCoy is an American scientist and business executive. She is the former CEO of Avon Products and former vice chairman and member of the office of the chairman of Johnson & Johnson, where she was responsible for the pharmaceutical and consumer business divisions of the company. She was appointed as the vice chairman in January 2011, after which she was named by Fortune Magazine, as the 10th woman on their list of "50 Most Powerful Women in Business", a list on which she has been included since 2008. In February 2012, she resigned her employment with Johnson & Johnson after 30 years and was subsequently named as the CEO of Avon Products. In August 2012, she was recognized as the 39th most powerful woman in the world by Forbes Magazine.

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations.

<span class="mw-page-title-main">Albert Bourla</span> CEO of Pfizer

Albert Bourla is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

William C. Steere Jr. is a former chief executive officer of Pfizer. He is also a member of the board of directors of the New York Botanical Garden. While Steere was CEO of Pfizer, the company acquired Warner-Lambert and brought to market blockbuster drugs including Viagra, Zoloft, and Zithromax. His decision to triple research expenditures in 8 years, to $2.2 billion, was cited as a reason for the prosperity of Pfizer during his tenure, a period in which sales of the company doubled.

References

  1. ↑ William C. Weldon, Business Week
  2. ↑ "Johnson & Johnson History: 2002", Johnson & Johnson website
  3. 1 2 "About Quinnipiac Alumni in Business". Quinnipiac University . Retrieved December 28, 2011.
  4. ↑ Johnson, Linda A. (June 27, 2006). "Johnson & Johnson Buys Pfizer Consumer Brands". The Washington Post . Retrieved December 28, 2011.
  5. ↑ Peterson, Melody (February 24, 2002). "Private Sector; From the Ranks, Unassumingly". The New York Times . Retrieved June 19, 2015.
  6. ↑ "2009 CEO Compensation for William C. Weldon", Equilar
  7. ↑ Finkelstein, Sydney (December 28, 2011). "The Worst C.E.O.'s of 2011". The New York Times . Retrieved December 27, 2011.
  8. ↑ "On Weldon's Watch: Recalls from Johnson & Johnson from 2009 to 2010". Harvard Business Review . Retrieved July 26, 2013.
  9. ↑ http://files.shareholder.com/downloads/JNJ/0x0x180981/674ABA8C-31FE-4482-8F08-246986C273F5/jnj_2002annual.pdf [ bare URL PDF ]
  10. ↑ http://www.jnj.com/sites/default/files/pdf/JNJ2012annualreport.pdf [ bare URL PDF ]
  11. ↑ "Johnson & Johnson CEO Weldon to Get $143.5 Million in Retirement". Businessweek. Archived from the original on March 17, 2012. Retrieved May 22, 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.